TELA
Bullish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 4.20 · operating margin -42% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Interesting trend — weekly bias down
ACHAT TOTAL: 177 500 titres (~186 015,75 $ US)
- Insiders
- Capper Joseph HGetz Heather C
- Total bought
-
$186,016
Avg buy (VWAP, 90d window) $1.05 vs last close $1.27 (+21.2%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-17
- Liquidity
- Illiquid $363,914/day · 20d vol
- Last synced
-
2026-09-24 21:10:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-17 | Capper Joseph H | Buy | 25,000 | $1.22 | $30,530 | Form 4 |
| 2026-09-16 | Capper Joseph H | Buy | 50,000 | $1.17 | $58,265 | Form 4 |
| 2026-09-15 | Capper Joseph H | Buy | 50,000 | $1.06 | $52,940 | Form 4 |
| 2026-09-14 | Capper Joseph H | Buy | 25,000 | $1.02 | $25,502 | Form 4 |
| 2026-08-17 | Getz Heather C | Buy | 12,500 | $0.66 | $8,311 | Form 4 |
| 2026-08-14 | Getz Heather C | Buy | 15,000 | $0.70 | $10,467 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signalScored 2026-09-23
TELA's insider cluster buying (177,500 shares) provides a moderate catalyst signal, but the weak financial health scores (liquidity: 45, fundamentals trend: 35) and severely stressed balance sheet undermine conviction.
The first sentence of the analysis written for TELA on 2026-09-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% | |
| Ebit Margin | -41.6% | -47.2% | -70.9% | -97.2% | -100.7% | |
| Ebitda Margin | -40.3% | -45.7% | -69.5% | -94.3% | -98.9% | |
| Operating Profit Margin | -42.0% | -49.2% | -75.4% | -94.2% | -100.0% | |
| Pretax Profit Margin | -48.1% | -54.8% | -79.8% | -106.9% | -112.9% | |
| Continuous Operations Profit Margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | |
| Net Profit Margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | |
| Bottom Line Profit Margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | |
| Current Ratio | 4.205 | 5.005 | 4.227 | 5.035 | 5.584 | |
| Quick Ratio | 3.592 | 4.186 | 3.452 | 4.084 | 4.860 | |
| Solvency Ratio | -0.504 | -0.626 | -0.775 | -0.805 | -0.771 | |
| Cash Ratio | 2.829 | 3.377 | 2.754 | 3.388 | 4.154 | |
| Price To Earnings Ratio | -1.422 | -2.271 | -3.245 | -4.212 | -5.565 | |
| Price To Earnings Growth Ratio | 0.038 | 0.065 | 0.128 | -0.225 | -1.773 | |
| Forward Price To Earnings Growth Ratio | 0.038 | 0.065 | 0.128 | -0.225 | -1.773 | |
| Price To Earnings Diluted Ratio | -1.422 | -2.271 | -3.245 | -4.212 | -5.565 | |
| Price To Earnings Diluted Growth Ratio | 0.038 | 0.065 | 0.128 | -0.225 | -1.773 | |
| Price To Book Ratio | 8.775 | 3.027 | 8.018 | 13.078 | 9.218 | |
| Price To Sales Ratio | 0.690 | 1.243 | 2.590 | 4.517 | 6.288 | |
| Price To Free Cash Flow Ratio | -1.932 | -2.023 | -3.651 | -4.389 | -5.965 | |
| Price To Operating Cash Flow Ratio | -1.963 | -2.071 | -3.705 | -4.591 | -6.088 | |
| Debt To Assets Ratio | 0.684 | 0.493 | 0.548 | 0.611 | 0.504 | |
| Debt To Equity Ratio | 8.816 | 1.513 | 2.265 | 2.898 | 1.567 | |
| Debt To Capital Ratio | 0.898 | 0.602 | 0.694 | 0.743 | 0.610 | |
| Long Term Debt To Capital Ratio | 0.898 | 0.591 | 0.682 | 0.736 | 0.610 | |
| Financial Leverage Ratio | 12.897 | 3.069 | 4.134 | 4.743 | 3.112 | |
| Working Capital Turnover Ratio | 1.337 | 1.182 | 1.115 | 0.841 | 0.471 | |
| Operating Cash Flow Ratio | -1.570 | -2.667 | -2.408 | -3.285 | -2.878 | |
| Operating Cash Flow Sales Ratio | -0.352 | -0.600 | -0.699 | -0.984 | -1.033 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.016 | 1.024 | 1.015 | 1.046 | 1.021 | |
| Debt Service Coverage Ratio | -6.211 | -5.405 | -7.020 | -8.895 | -8.102 | |
| Interest Coverage Ratio | -6.436 | -6.449 | -8.439 | -9.629 | -8.188 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -76.321 | -72.313 | -119.847 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.507 | -0.966 | -0.955 | -0.983 | -0.966 | |
| Capital Expenditure Coverage Ratio | -62.989 | -42.058 | -66.869 | -21.767 | -48.536 | |
| Dividend Paid And Capex Coverage Ratio | -62.989 | -42.058 | -66.869 | -21.767 | -48.536 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.861 | -2.416 | -3.628 | -4.775 | -5.930 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.7% | ▲0.6% | ▲1.2% |
| Ebit Margin | -41.5% | ▲5.6% | ▲29.9% |
| Ebitda Margin | -40.3% | ▲5.4% | ▲29.5% |
| Operating Profit Margin | -42.0% | ▲7.2% | ▲30.1% |
| Pretax Profit Margin | -48.1% | ▲6.7% | ▲32.4% |
| Continuous Operations Profit Margin | -48.4% | ▲6.2% | ▲32.2% |
| Net Profit Margin | -48.4% | ▲6.2% | ▲32.2% |
| Bottom Line Profit Margin | -48.4% | ▲6.2% | ▲32.2% |
| Current Ratio | 4.205 | ▼-0.800 | ▼-0.607 |
| Quick Ratio | 3.592 | ▼-0.594 | ▼-0.443 |
| Solvency Ratio | -0.504 | ▲0.122 | ▲0.193 |
| Cash Ratio | 2.829 | ▼-0.548 | ▼-0.472 |
| Price To Earnings Ratio | -1.422 | ▲0.849 | ▲1.921 |
| Price To Earnings Growth Ratio | 0.038 | ▼-0.027 | ▲0.391 |
| Forward Price To Earnings Growth Ratio | 0.038 | ▼-0.027 | ▲0.391 |
| Price To Earnings Diluted Ratio | -1.422 | ▲0.849 | ▲1.921 |
| Price To Earnings Diluted Growth Ratio | 0.038 | ▼-0.027 | ▲0.391 |
| Price To Book Ratio | 8.775 | ▲5.748 | ▲0.352 |
| Price To Sales Ratio | 0.690 | ▼-0.553 | ▼-2.376 |
| Price To Free Cash Flow Ratio | -1.933 | ▲0.091 | ▲1.660 |
| Price To Operating Cash Flow Ratio | -1.963 | ▲0.108 | ▲1.720 |
| Debt To Assets Ratio | 0.683 | ▲0.191 | ▲0.116 |
| Debt To Equity Ratio | 8.816 | ▲7.303 | ▲5.404 |
| Debt To Capital Ratio | 0.898 | ▲0.296 | ▲0.189 |
| Long Term Debt To Capital Ratio | 0.898 | ▲0.307 | ▲0.195 |
| Financial Leverage Ratio | 12.897 | ▲9.828 | ▲7.306 |
| Working Capital Turnover Ratio | 1.337 | ▲0.155 | ▲0.348 |
| Operating Cash Flow Ratio | -1.570 | ▲1.097 | ▲0.992 |
| Operating Cash Flow Sales Ratio | -0.351 | ▲0.249 | ▲0.382 |
| Free Cash Flow Operating Cash Flow Ratio | 1.016 | ▼-0.008 | ▼-0.008 |
| Debt Service Coverage Ratio | -6.211 | ▼-0.806 | ▲0.916 |
| Interest Coverage Ratio | -6.436 | ▲0.013 | ▲1.392 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲76.321 | ▲53.696 |
| Operating Cash Flow Coverage Ratio | -0.507 | ▲0.459 | ▲0.368 |
| Capital Expenditure Coverage Ratio | -62.989 | ▼-20.931 | ▼-14.545 |
| Dividend Paid And Capex Coverage Ratio | -62.989 | ▼-20.931 | ▼-14.545 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.861 | ▲0.554 | ▲1.861 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $55.4M | $86.1M | $151.4M | $187.1M | $185.3M | |
| Enterprise value | $60.2M | $76.5M | $147.4M | $186.5M | $172.8M | |
| EV / Sales | 0.75x | 1.10x | 2.52x | 4.50x | 5.87x | |
| EV / Op. cash flow | -2.13x | -1.84x | -3.61x | -4.58x | -5.68x | |
| EV / Free cash flow | -2.10x | -1.80x | -3.56x | -4.38x | -5.56x | |
| EV / EBITDA | -1.86x | -2.42x | -3.63x | -4.78x | -5.93x | |
| Net debt / EBITDA | -0.15x | 0.30x | 0.10x | 0.01x | 0.43x | |
| Current ratio | 4.21x | 5.00x | 4.23x | 5.04x | 5.58x | |
| Income quality | 0.73x | 1.10x | 0.88x | 0.92x | 0.92x | |
| Graham net-net | -$0 | $0 | $0 | -$0 | $1 | |
| Tax burden | 100.6% | 99.6% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 115.7% | 116.2% | 112.6% | 110.1% | 112.1% | |
| Working capital | $57.6M | $62.5M | $54.8M | $50.0M | $48.5M | |
| Invested capital | $62.7M | $68.3M | $60.8M | $55.5M | $52.0M | |
| Return on assets | -47.7% | -43.3% | -59.8% | -65.3% | -53.2% | |
| Operating ROA | -40.0% | -41.3% | -60.4% | -59.8% | -39.5% | |
| Return on tangible assets | -48.5% | -44.2% | -61.5% | -67.8% | -55.2% | |
| Return on equity | -615.1% | -133.0% | -247.1% | -309.7% | -165.6% | |
| Return on invested capital | -53.2% | -47.0% | -71.5% | -69.9% | -56.7% | |
| Return on capital employed | -53.2% | -47.6% | -72.2% | -70.3% | -56.7% | |
| Earnings yield | -70.1% | -43.9% | -30.8% | -23.7% | -18.0% | |
| Free cash flow yield | -51.7% | -49.4% | -27.4% | -22.8% | -16.8% | |
| Capex / Op. cash flow | -1.6% | -2.4% | -1.5% | -4.6% | -2.1% | |
| Capex / Depreciation | 44.4% | 97.7% | 75.6% | 157.7% | 117.2% | |
| Capex / Sales | 0.6% | 1.4% | 1.0% | 4.5% | 2.1% | |
| SG&A / Sales | 98.3% | 114.5% | 127.6% | 137.9% | 140.9% | |
| R&D / Sales | 11.5% | 12.7% | 16.5% | 21.6% | 22.9% | |
| Stock comp / Sales | 4.7% | 6.3% | 8.6% | 9.6% | 12.4% | |
| Intangibles / Total assets | 1.7% | 2.0% | 2.7% | 3.7% | 3.7% | |
| Days sales outstanding | 47d | 53d | 61d | 58d | 52d | |
| Days payables outstanding | 32d | 34d | 33d | 39d | 83d | |
| Operating cycle | 202d | 258d | 323d | 358d | 315d | |
| Cash conversion cycle | 170d | 223d | 290d | 319d | 232d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-35.7%EV / Sales ▼-32.1%EV / EBITDA ▲+23.0%EV / Op. cash flow ▼-0.293Earnings yield ▼-0.262
Profitability
Return on equity ▼-4.821Return on assets ▼-0.044Return on invested capital ▼-0.062Return on capital employed ▼-0.056Operating ROA ▲+0.013Income quality ▼-0.372Tax burden ▲+0.010
Efficiency
Days sales outstanding ▼-6.139Days payables outstanding ▼-1.855Operating cycle ▼-55.598Cash conversion cycle ▼-53.743Capex / Sales ▼-0.009R&D / Sales ▼-0.012
Balance-sheet strength
Current ratio ▼-0.800Net debt / EBITDA ▼-0.452Working capital ▼-4867000.000Invested capital ▼-5597999.000Intangibles / Total assets ▼-0.003
Change over 5 years
Valuation
Market cap ▼-70.1%EV / Sales ▼-87.2%EV / EBITDA ▲+68.6%EV / Op. cash flow ▲+3.545Earnings yield ▼-0.521
Profitability
Return on equity ▼-4.495Return on assets ▲+0.055Return on invested capital ▲+0.035Return on capital employed ▲+0.035Operating ROA ▼-0.005Income quality ▼-0.188Tax burden ▲+0.006
Efficiency
Days sales outstanding ▼-5.406Days payables outstanding ▼-50.236Operating cycle ▼-112.822Cash conversion cycle ▼-62.586Capex / Sales ▼-0.016R&D / Sales ▼-0.114
Balance-sheet strength
Current ratio ▼-1.380Net debt / EBITDA ▼-0.575Working capital ▲+9126000.000Invested capital ▲+10724000.000Intangibles / Total assets ▼-0.020
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-21 Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) Director Joseph Capper bought 25,000 shares of TELA Bio stock in a transaction that occurred on Thursday, September 17th. The shares were acquired at an average price of $1.22 per share, for a total transaction of $30,500.00. Following the completion of the transaction, the director directly owned
- 2026-09-10 TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Volatility and Risk Baxter International has a beta
- 2026-08-31 TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
- 2026-08-11 TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
- 2026-08-10 TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.
- 2026-08-05 TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company''s newly-hired Chief Executive Officer, Heather Getz, with a grant date of August 3, 2026 (the "Getz Grant Date"). The stock options consist of (i) stock options to purchase 1,365,000 shares of common stock (the “Standard Options”) and (ii) premium-priced stock options to purchase 1,005,000 shares of common stock (the “Premium-Options”). Additionally, the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 95,500 shares of its common stock to 11 newly-hired employees, with a grant date of August 4, 2026. The stock options and the restricted stock units discussed above were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Ms. Getz''s and each individual''s employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
- 2026-08-04 TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today.
- 2026-07-29 TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference.
- 2026-07-20 TELA Bio to Announce Second Quarter 2026 Financial Results MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2026 financial results on Monday, August 10, 2026.